Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 12/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16619160 | 0.99 | IDE (0.37) | IDEHTR6PDE4APDE4BPDE4C | |
| SCHEMBL16626372 | 0.92 | HTR6 (0.40) | IDEHTR6CYP19A1NAMPT | |
| Hydrochloric Acid SCHEMBL16619123 | 0.91 | HTR6 (0.39) | IDEHTR6CYP19A1NAMPT | |
| SCHEMBL16626409 | 0.88 | HTR6 (0.44) | IDEHTR6CYP19A1FGFR4HTR2C | |
| Hydrochloric Acid SCHEMBL16618675 | 0.87 | HTR6 (0.43) | IDEHTR6CYP19A1FGFR4HTR2C | |
| SCHEMBL16626415 | 0.87 | CYP19A1 (0.43) | IDEHTR6PDE4APDE4BPDE4C | |
| SCHEMBL16626711 | 0.87 | IDE (0.37) | IDEHTR6PDE4APDE4BPDE4C | |
| SCHEMBL16626671 | 0.86 | HTR6 (0.41) | IDEHTR6PDE4APDE4BPDE4C | |
| SCHEMBL16626421 | 0.86 | TBXAS1 (0.40) | IDEHTR6CYP19A1FGFR4NAMPT | |
| Hydrochloric Acid SCHEMBL16619105 | 0.86 | CYP19A1 (0.42) | IDEHTR6PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052484-B1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAE WOONG PHARMA (KR) | 2018-03-21 | — | — | EP | claimed |
| CN-105612150-A | Sulfonylindole derivatives and process for producing the same | DAE WOONG PHARMA | 2016-05-25 | — | — | CN | claimed |
| EP-3052484-B1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAE WOONG PHARMA (KR) | 2018-03-21 | — | — | EP | disclosed |
| US-9676714-B2 | Sulfonylindole derivatives and method for preparing the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9676714-B2 | Sulfonylindole derivatives and method for preparing the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-04 | — | — | US | disclosed |
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-04 | — | — | US | disclosed |
| WO-2015050412-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | GIPR, PGC, SI | IDE 2586/4885HTR6 166/4885PDE4A 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.